Differential disruption of conditioned ejaculatory preference in the male rat based on different sensory modalities by micro-infusions of naloxone to the medial preoptic area or ventral tegmental area.


Journal

Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 27 02 2019
accepted: 14 07 2019
pubmed: 31 7 2019
medline: 4 3 2020
entrez: 31 7 2019
Statut: ppublish

Résumé

Male rats trained to associate a neutral odor or rodent jacket on a female with their post-ejaculatory reward state display a preference to ejaculate with females bearing the odor or jacket. This conditioned ejaculatory preference (CEP) can be shifted by systemic administration of the opioid antagonist naloxone (NAL) during training, such that NAL-trained males distribute their ejaculations to females without the cue, relative to saline (SAL)-trained males. The present study examined two brain sites, the medial preoptic area (mPOA) or ventral tegmental area (VTA), where the opioid reward state might be induced. Sexually naïve Long-Evans males were implanted with bilateral guide cannula aimed at either site before they underwent multi-ejaculatory conditioning trials at 4-day intervals with sexually receptive females that bore either an almond odor or rodent tethering jacket. Infusions of NAL (1 μl/side) or SAL (1 μl/side) were made prior to each conditioning trial. All males were infused with SAL prior to a final open-field choice test with two sexually receptive females, one scented and the other unscented, or one jacketed and the other unjacketed. Males previously conditioned with SAL in either region showed significant CEP. In contrast, prior infusions of NAL to the mPOA shifted the preference towards the unfamiliar female, whereas prior infusions to the VTA abolished CEP for the odor. Subsequent detection of Fos protein induced by the cue showed that, relative to SAL-treated males, prior experience with NAL in the mPOA suppressed Fos in both the mPOA and VTA, whereas prior experience with NAL in to the VTA suppressed Fos in the VTA alone. Opioid antagonism in the mPOA produces a state of non-reward whereas in the VTA, it produces a state in which the odor does not acquire incentive properties.

Identifiants

pubmed: 31359118
doi: 10.1007/s00213-019-05334-9
pii: 10.1007/s00213-019-05334-9
doi:

Substances chimiques

Narcotic Antagonists 0
Naloxone 36B82AMQ7N

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3613-3623

Subventions

Organisme : CIHR
ID : MOP-74563
Pays : Canada
Organisme : Consejo Nacional de Ciencia y Tecnología de Chile
ID : Graduate Studentship
Organisme : Fonds de Recherche du Québec - Santé
ID : Center Grant for the CSBN

Commentaires et corrections

Type : ErratumIn

Références

Neuron. 2012 Jun 7;74(5):858-73
pubmed: 22681690
eNeuro. 2017 Jan 9;3(6):
pubmed: 28083561
Behav Neurosci. 2009 Oct;123(5):992-9
pubmed: 19824765
Behav Brain Res. 2002 Apr 1;131(1-2):47-55
pubmed: 11844571
Front Syst Neurosci. 2017 Jun 08;11:42
pubmed: 28642689
Neuropsychopharmacology. 2004 Apr;29(4):718-30
pubmed: 14694350
Eur J Neurosci. 2003 Aug;18(3):667-74
pubmed: 12911762
Pharmacol Biochem Behav. 1990 Mar;35(3):643-50
pubmed: 1971113
Brain Res. 2013 Dec 6;1541:22-32
pubmed: 24140428
Nat Rev Urol. 2012 Sep;9(9):486-98
pubmed: 22926422
Eur J Pharmacol. 1981 Mar 26;70(3):279-85
pubmed: 6262094
Psychopharmacology (Berl). 1985;87(2):225-32
pubmed: 3931151
Neuroscience. 2004;124(1):11-21
pubmed: 14960335
Socioaffect Neurosci Psychol. 2012 Mar 15;2:14874
pubmed: 24693343
Behav Neurosci. 2013 Apr;127(2):293-302
pubmed: 23565937
Behav Neurosci. 1990 Feb;104(1):177-82
pubmed: 2156520
Behav Neurosci. 2013 Jun;127(3):451-7
pubmed: 23544595
Psychopharmacology (Berl). 1991;104(2):265-74
pubmed: 1876671
Front Neuroanat. 2015 Sep 04;9:112
pubmed: 26388742
Behav Neurosci. 2019 Apr;133(2):198-202
pubmed: 30714805
Brain Res Brain Res Rev. 1995 Sep;21(2):162-84
pubmed: 8866673
Trends Neurosci. 1988 Jul;11(7):308-14
pubmed: 2465635
Prog Neurobiol. 1992 Sep;39(3):247-79
pubmed: 1502338
Behav Brain Res. 1986 May;20(2):231-40
pubmed: 3524604
Neuropsychopharmacology. 2016 Jun;41(7):1897-906
pubmed: 26647972
Psychopharmacology (Berl). 1992;106(3):391-6
pubmed: 1315063
Neuroscience. 2003;117(4):971-9
pubmed: 12654349
Psychopharmacology (Berl). 1990;102(2):243-56
pubmed: 2274607
Neuroscience. 2007 Sep 7;148(3):623-32
pubmed: 17693029
Trends Neurosci. 2015 Apr;38(4):217-25
pubmed: 25637939
Neurosci Lett. 1997 Sep 19;233(2-3):65-8
pubmed: 9350833
Behav Neurosci. 1993 Oct;107(5):812-8
pubmed: 8280390
Pharmacol Biochem Behav. 2014 Jun;121:124-31
pubmed: 24239788
Physiol Behav. 1986;37(2):329-35
pubmed: 3488558
J Comp Neurol. 1994 Dec 15;350(3):412-38
pubmed: 7884049
Pharmacol Biochem Behav. 1992 Mar;41(3):559-65
pubmed: 1584835
Horm Behav. 2009 Jan;55(1):93-7
pubmed: 18835271
Neuroscience. 1987 Dec;23(3):1063-73
pubmed: 2830562
Socioaffect Neurosci Psychol. 2016 Oct 25;6:31883
pubmed: 27799081
Neurosci Biobehav Rev. 1987 Spring;11(1):1-34
pubmed: 3554038
Regul Pept. 1991 Sep 3;35(3):177-87
pubmed: 1722047
Brain Res. 1996 Aug 5;729(1):20-8
pubmed: 8874873
J Comp Neurol. 1988 Oct 15;276(3):442-59
pubmed: 2903870
Psychopharmacology (Berl). 2007 Apr;191(3):391-431
pubmed: 17072591
Eur J Pharmacol. 2000 Sep 29;405(1-3):89-101
pubmed: 11033317
Neuroscience. 2006;137(4):1259-76
pubmed: 16388908
Physiol Behav. 2001 Jul;73(4):457-69
pubmed: 11495649
Trends Neurosci. 2009 Oct;32(10):517-24
pubmed: 19758714
J Neurosci. 1999 Jan 1;19(1):456-63
pubmed: 9870973
Psychopharmacology (Berl). 1995 Dec;122(4):330-5
pubmed: 8657829
Psychopharmacology (Berl). 1999 Feb;142(2):200-8
pubmed: 10102773
Physiol Behav. 2001 Feb;72(3):355-8
pubmed: 11274677
Arch Sex Behav. 2012 Feb;41(1):31-62
pubmed: 22402996
Physiol Rev. 1991 Jan;71(1):155-234
pubmed: 1986388
Front Neuroendocrinol. 2007 Oct;28(4):161-78
pubmed: 17624413
J Comp Neurol. 2005 Dec 5;493(1):115-21
pubmed: 16254990
Behav Neurosci. 2019 Apr;133(2):188-197
pubmed: 30714804
Behav Neurosci. 1995 Feb;109(1):123-34
pubmed: 7734068
J Sex Med. 2009 Jun;6(6):1506-1533
pubmed: 19453889
Pharmacol Biochem Behav. 1987 Apr;26(4):781-9
pubmed: 3602035
Brain Res. 1990 Jul 30;524(1):77-84
pubmed: 1976031
Behav Brain Res. 2016 May 15;305:218-22
pubmed: 26947755
Ann N Y Acad Sci. 1988;537:206-15
pubmed: 3059924
Psychopharmacology (Berl). 1990;101(1):118-25
pubmed: 2343072
Horm Behav. 1999 Jun;35(3):224-40
pubmed: 10373335

Auteurs

Gonzalo R Quintana (GR)

Centre for Studies in Behavioral Neurobiology, Department of Psychology, Concordia University, Montréal, QC, H4B 1R6, Canada.

Morgan Birrel (M)

Centre for Studies in Behavioral Neurobiology, Department of Psychology, Concordia University, Montréal, QC, H4B 1R6, Canada.

Sarah Marceau (S)

Centre for Studies in Behavioral Neurobiology, Department of Psychology, Concordia University, Montréal, QC, H4B 1R6, Canada.

Narges Kalantari (N)

Centre for Studies in Behavioral Neurobiology, Department of Psychology, Concordia University, Montréal, QC, H4B 1R6, Canada.

James Bowden (J)

Centre for Studies in Behavioral Neurobiology, Department of Psychology, Concordia University, Montréal, QC, H4B 1R6, Canada.

Yvonne Bachoura (Y)

Centre for Studies in Behavioral Neurobiology, Department of Psychology, Concordia University, Montréal, QC, H4B 1R6, Canada.

Eric Borduas (E)

Centre for Studies in Behavioral Neurobiology, Department of Psychology, Concordia University, Montréal, QC, H4B 1R6, Canada.

Valerie Lemay (V)

Centre for Studies in Behavioral Neurobiology, Department of Psychology, Concordia University, Montréal, QC, H4B 1R6, Canada.

Jason W Payne (JW)

Centre for Studies in Behavioral Neurobiology, Department of Psychology, Concordia University, Montréal, QC, H4B 1R6, Canada.

Conall Mac Cionnaith (CM)

Centre for Studies in Behavioral Neurobiology, Department of Psychology, Concordia University, Montréal, QC, H4B 1R6, Canada.

James G Pfaus (JG)

Centre for Studies in Behavioral Neurobiology, Department of Psychology, Concordia University, Montréal, QC, H4B 1R6, Canada. jpfaus@uv.mx.
Centro de Investigaciones Cerebrales, Universidad Veracruzana, CP 91193, Xalapa, VER, Mexico. jpfaus@uv.mx.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH